Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Trial Profile

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PolyPEPI 1018 (Primary) ; Bevacizumab; Fluoropyrimidine derivatives
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; First in man
  • Acronyms OBERTO
  • Sponsors Treos Bio
  • Most Recent Events

    • 07 Nov 2019 According to a Treos Bio media release, results will be presented at SITC 2019.
    • 26 Sep 2019 According to a Treos Bio media release, Joleen M. Hubbard is the principal investigator of this trial at the Mayo Clinic.
    • 26 Sep 2019 According to a Treos Bio media release, data will be prersented at the 2019 European Society of Medical Oncology (ESMO) annual congress in Barcelona on September 29, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top